Skip to main content

Table 1 CAR T cell therapy in lymphoma

From: Novel and emerging therapies for B cell lymphoma

CAR T cell product Axicabtagene ciloleucel (Yescarta) Tisagenlecleucel (Kymriah) Lisocabtagene maraleucel
Costimulation domain CD-28 4-1BB 4-1BB
Vector Retrovirus Lentivirus Lentivirus
Conditioning regimen Fludarabine, cyclophosphamide Fludarabine, cyclophosphamide, or bendamustine Fludarabine, cyclophosphamide
Pivotal trial ZUMA-1 (N = 108) JULIET (N = 111) TRANSCEND-NHL-001 (N = 102)
Histology DLBCL, tFL, PMBCL DLBCL, tFL DLBCL,PMBCL, FL, tFL
CAR T cell dosage 2 × 106 cells/kg 3 × 108 cells/kg 1 × 108 cells/kg
ORR 83% 52% 75%
CR 58% 40% 55%
Median DOR (months) 11.1 (95% CI, 4.2—NE) NR (95% CI, 10—NR) NA
Overall survival 24-month survival, 50.5% (95% CI 40.2–59.7) 11.7 months (95% CI, 6.6—NE) NA
Any grade CRS/NT 93%/64 % 58%/21% 37%/25 %
Grade ≥ 3 CRS 13% 22% 1%
Grade ≥ 3 NT 28% 12% 15%
Tocilizumab/steroid usage 43%/27% 15%/10% 17%/21%
Grade 5 AEs 4% None None
Reference [11, 13] [9, 14] [12, 15]
  1. Abbreviations: N number of patients, ORR overall response rate, CR complete response rate, CRS cytokine release syndrome, NT neurotoxicity, DOR duration of response, CAR chimeric antigen receptor, AE adverse event, DLBCL diffuse large B cell lymphoma, tFL transformed follicular lymphoma, FL follicular lymphoma, PMBCL primary mediastinal B cell lymphoma, NE not estimated, NR not reached, NA data unavailable